Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit
Open Access
- 7 February 2017
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 6 (2) , e1231291
Abstract
Purpose: Patients with regionally advanced melanoma were treated with neoadjuvant ipilimumab in a previously reported study (PLOS One 2014). Gene expression profiles of tumors of treated patients were investigated for their association with immunotherapeutic benefit. Methods: Patients were treated with ipilimumab (10 mg/kg intravenously every 3 weeks × 2 doses) before and after surgery. Tumor specimens were obtained at baseline and at definitive surgery (weeks 6–8). Gene expression profiling was performed on the tumor biopsies of 27 patients. The primary endpoint was mRNA expression profiling using U133A 2.0 Affymetrix gene chips. Significance analysis of microarrays was performed to test the association of each gene with outcome. Pathway analysis was performed using Ingenuity Pathway Analysis software. The Benjamini and Hochberg method was used to adjust for multiple testing in the pathway analysis. Results: Pathway analysis identified biologically relevant pathways enriched with genes that are significantly associated with clinical outcome at baseline in relation to relapse-free survival (RFS) and disease non-progression (as assessed preoperatively at week 6) as well as early on-treatment (RFS and overall survival). The molecules and pathways that achieved differential expression of highest statistical significance were notably immune related. Association of the gene signature with clinical outcome overlapped between baseline and on-treatment specimens and across clinical endpoints tested. Conclusion: Gene expression profiling identified a signature reflecting an immune active and proinflammatory tumor microenvironment that derived clinical benefit from neoadjuvant ipilimumab at baseline and early on-treatment. These findings warrant further investigation in relation to ipilimumab and other immunotherapeutics.Keywords
This publication has 18 references indexed in Scilit:
- An immune-active tumor microenvironment favors clinical response to ipilimumabCancer Immunology, Immunotherapy, 2011
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaJournal of Translational Medicine, 2011
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- What Is the Role of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?The Oncologist, 2009
- Gastrosplenic Fistula From Hodgkin's LymphomaJournal of Clinical Oncology, 2009
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell RecruitmentCancer Research, 2009
- Principles and use of anti-CTLA4 antibody in human cancer immunotherapyCurrent Opinion in Immunology, 2006
- Intracellular Trafficking of CTLA-4 and Focal Localization Towards Sites of TCR EngagementImmunity, 1996